Prodrug Strategies for Critical Drug Developability Issues: Part I

Area of Science:

• Pharmaceutical Sciences
• Medicinal Chemistry
• Drug Discovery

Background:

• Drug development is a lengthy, costly, and high-attrition process, with many candidates failing due to poor pharmacokinetics (PK) or efficacy.
• Traditional structure-activity relationship (SAR/SPR) studies to improve drug candidates are often time-consuming and labor-intensive.

Discussion:

• Prodrug strategies provide an efficient alternative to extensive SAR/SPR studies for enhancing drug developability.
• Approximately 20% of drugs approved between 2008 and 2020 were prodrugs, highlighting the success of this approach.
• Recent applications include addressing delivery challenges for gasotransmitters like NO, H2S, CO, and SO2.

Key Insights:

• Prodrugs can overcome critical drug developability issues, including poor PK profiles and lack of efficacy.
• This strategy circumvents the need for extensive chemical modification, saving significant time and resources.
• The successful application of prodrugs extends to diverse therapeutic areas and novel molecular classes like gasotransmitters.

Outlook:

• Further exploration of prodrug strategies is crucial for optimizing drug development pipelines.
• Continued research into prodrug design will accelerate the delivery of improved therapeutics for various diseases.
• The thematic issue highlights innovative prodrug approaches for anticancer, CNS, and gasotransmitter-based therapies.